Introduction b-Blocker therapy plays a major role in the treatment of cardiovascular
diseases. For many years b-blockers were used for their antiischaemic, antiarryhthmic and …

Ventricular tachycardia in nonischemic heart failure (HF) initiates by a nonreentrant
mechanism that appears to be due to triggered activity primarily from delayed …

Background Patients with nonischemic dilated cardiomyopathy are at substantial risk for
sudden death from cardiac causes. However, the value of prophylactic implantation of an …

Objectives: The purpose of this study was to test how surgical ventricular restoration (SVR)
affects early and late survival in a registry of 1,198 post-anterior infarction congestive heart …

Objectives: We performed genetic investigations of cardiac troponin T (TNNT2) and troponin
C (TNNC1) in 235 consecutive patients with idiopathic dilated cardiomyopathy (DCM) to …

β-Adrenergic blockers are one of the most frequently prescribed cardiovascular drugs.
Numerous β-blockers are available for clinical use. Although these agents differ …

Objectives: This study was designed to evaluate the cost-effectiveness of screening patients
with a B-type natriuretic peptide (BNP) blood test to identify those with depressed left …

Aims: Heart failure (HF) treatment guidelines of the ESC recommend ACE-inhibitors (ACE-I)
as first-line treatment and β-blockers added if patients remain symptomatic. CARMEN …

Abstract β-Adrenoceptor stimulation serves as the most powerful means to increase cardiac
output in response to stress or exercise. However, sustained β-adrenoceptor stimulation …

Objectives: We evaluated the interaction of angiotensin-converting enzyme (ACE) inhibitor
therapy with the effect of the ACE D/I polymorphism on heart failure survival. Background …